The Landmark Surgical Trials of the National Surgical Adjuvant Breast and Bowel Project
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States World Journal of Surgery
(Impact Factor: 2.64).
08/2006; 30(7):1138-46. DOI: 10.1007/s00268-005-0552-5
In this paper we provide a summary of several of the completed and ongoing surgical trials of the National Surgical Adjuvant Breast and Bowel Project, one of the cancer cooperative trials groups supported by the US National Cancer Institute.
Available from: unjbg.edu.pe
- "One of the reasons for this is that until the development of taxanes, there were no candidate non–cross-resistant regimens with promising activity that could be tested in this setting; however, the demonstration of significant antitumor activity with taxanes in patients resistant to anthracyclines provided the opportunity to revisit the above question in a randomized clinical trial. Such a currently ongoing trial is the International Breast Cancer Study Group (IBCSG) 27-02/NSABP B-37, which randomizes patients who have resected in-breast recurrence or other loco-regional recurrence to chemotherapy or observation (in addition to hormonal therapy for hormonereceptor–positive tumors)  "
[Show abstract] [Hide abstract]
ABSTRACT: The National Surgical Adjuvant Breast Project (NSABP) is a clinical trials cooperative group funded by the National Cancer Institute that has been responsible for the majority of prospective, randomized studies that have defined standards of breast cancer care in the United States during the past 4 decades. This article summarizes the design of and findings from a selection of their landmark studies. Results from their many successfully completed trials have been reported as subset analyses, pooled analyses, and retrospective studies. This article focuses on presenting the study designs, aims, and primary endpoint results of these studies.
Surgical Clinics of North America 05/2007; 87(2):279-305, vii. DOI:10.1016/j.suc.2007.02.005 · 1.88 Impact Factor
Annals of Surgical Oncology 09/2007; 14(8):2182-4. DOI:10.1245/s10434-007-9374-z · 3.93 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Sentinel lymph node biopsy (SLNB) is considered a standard of care in the staging of breast cancer. The objective was to examine our experience with reoperative SLNB.
We identified 19 patients in our breast cancer database who had a SLNB in the reoperative setting. All 19 patients had undergone previous breast-conserving surgery with either an axillary lymph node dissection or an SLNB. The reoperative sentinel lymph node (SLN) was identified using blue dye, radioisotope, or both.
The SLN was identified in 84% of the reoperative cases. Of these successful cases, both blue dye and radioisotope were used in five cases, and radioisotope alone was used in 11 cases. Radioisotope identified the SLN in the 100% of successful SLNB cases (P = .0003). There were 3 unsuccessful cases in which blue dye and radioisotope failed to identify the sentinel node.
Reoperative SLNB after previous axillary surgery is technically feasible.
American journal of surgery 11/2007; 194(4):491-3. DOI:10.1016/j.amjsurg.2007.07.011 · 2.29 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.